Anti-angiogenic compositions and methods of use

• US 6,846,841 B2
• Filed: 03/28/2002
• Issued: 01/25/2005
• Est. Priority Date: 07/19/1993
• Status: Expired due to Term

• Current Assignee: Surgical Specialties Corporation Limited (Ssc Holdco Ltd)
• Original Assignee: Angiotech Pharmaceuticals Incorporated
• Inventors: Hunter, William L., Machan, Lindsay S., Arsenault, A. Larry
• Primary Examiner(s): Kumar, Shailendra
• Application Number:
  US10/112,921
• Publication Number:
  US 20030004209A1
• Time in Patent Office: 1,034 Days
• Field of Search: 514/210, 514/250, 514/825, 514/826, 514/449, 424/424, 424/501, 424/502, 424/426
• US Class Current: 514/449
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 31/136 having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• CPC Class Codes: A61K 31/185 Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids hydroxamic acids A61K31/16; peroxy acids A61K31/327
• CPC Class Codes: A61K 31/203 Retinoic acids ; Salts thereof
• CPC Class Codes: A61K 31/335 having oxygen as the only ring hetero atom, e.g. fungichromin
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/50 the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• CPC Class Codes: A61K 47/6925 the form being a microcapsule, nanocapsule, microbubble or nanobubble
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/1658 Proteins, e.g. albumin, gelatin
• CPC Class Codes: A61K 9/167 with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface with further drug-free outer coating A61K9/5073
• CPC Class Codes: A61K 9/5153 : Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/7007 : Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61L 2300/416 : Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/606 : Coatings
• CPC Class Codes: A61L 2300/622 : Microcapsules
• CPC Class Codes: A61L 2430/36 : for embolization or occlusion, e.g. vaso-occlusive compositions or devices artificial blood vessels A61L27/507
• CPC Class Codes: A61L 31/10 : Macromolecular materials
• CPC Class Codes: A61L 31/145 : Hydrogels or hydrocolloids
• CPC Class Codes: A61L 31/16 : Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C07K 14/811 : Serine protease (E.C. 3.4.21) inhibitors
• CPC Class Codes: C08L 2203/02 : for biomedical use
• CPC Class Codes: C08L 23/08 : Copolymers of ethene C08L23/16 takes precedence
• CPC Class Codes: C08L 23/0815 : Copolymers of ethene with aliphatic 1-olefins
• CPC Class Codes: C08L 23/0853 : Vinylacetate
• CPC Class Codes: C08L 2312/00 : Crosslinking
• CPC Class Codes: C08L 2666/06 : Homopolymers or copolymers of unsaturated hydrocarbons; Derivatives thereof
• CPC Class Codes: C08L 2666/18 : Polyesters or polycarbonates according to C08L67/00 - C08L69/00; Derivatives thereof
• CPC Class Codes: C08L 67/04 : Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

Claims

1. A method for embolizing a blood vessel, comprising delivering into said vessel a therapeutically effective amount of a composition comprising a compound which disrupts microtubule function, wherein said compound is paclitaxel, or an analogue or derivative thereof, such that said blood vessel is effectively occluded.

2. The method according to claim 1 wherein said paclitaxel, or an analogue or derivative thereof is paclitaxel.

3. The method according to claim 1 or 2 wherein said composition further comprises a polymeric carrier.

4. The method according to claim 3 wherein said composition is formed into microspheres.

5. The method according to claim 3 wherein said polymeric carrier is poly(ethylene-vinyl acetate) crosslinked with 40% vinyl acetate.

6. The method according to claim 3, wherein said polymeric carrier is poly(lactic-co-glycolic acid).

7. The method according to claim 3 wherein said polymeric carrier is poly(caprolactone).

8. The method according to claim 3 wherein said polymeric carrier is poly(lactic acid).

9. The method according to claim 3 wherein said polymeric carrier is a copolymer of poly(lactic acid) and poly(caprolactone).

10. The method according to claim 3 wherein said polymeric carrier is a copolymer of poly(ethylene-vinyl acetate) crosslinked with 40% vinyl acetate, and poly(lactic acid).

11. The method according to claim 1 or 2 wherein said blood vessel nourishes a tumor.

12. The method according to claim 1 or 2 wherein said blood vessel nourishes a non-tumorigenic, angiogenesis-dependent disease.

13. The method according to claim 3 wherein said blood vessel nourishes a tumor.

14. The method according to claim 3 wherein said blood vessel nourishes a non-tumorigenic, angiogenesis-dependent disease.

15. The method according to claim 3 wherein said polymeric carrier is biodegradable.